Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL
Status:
Terminated
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different
ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and
help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such
as cyclophosphamide and prednisone, work in different ways to stop the growth of cancer
cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the
growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking
blood flow to the tumor. Giving rituximab together with cyclophosphamide, bortezomib, and
prednisone may kill more cancer cells.
PURPOSE: This clinical trial is studying how well giving rituximab together with
cyclophosphamide, bortezomib, and prednisone works as first-line therapy in treating patients
with stage III or stage IV follicular lymphoma or marginal zone lymphoma.
Phase:
N/A
Details
Lead Sponsor:
University of Miami University of Miami Sylvester Comprehensive Cancer Center